Cryptocurrency Tips

💰 Want to Profit from Cryptocurrency Tips Like the Pros?
👉 Discover the strategy that helped early adopters multiply their earnings.

Monday, August 17, 2026

Base B20 Token Standard: How Native Tokens Differ From ERC-20

Base B20 Token Standard: How Native Tokens Differ From ERC-20

Base just switched on something big for token builders: a native token standard called B20. If you’ve been minting ERC-20s for years, B20 looks familiar on the surface — but the guts are different. This piece breaks down what changed, why it matters for issuers and traders, and what to watch next.

We’ll compare B20 to ERC-20 in plain English, walk through how the factory actually works, and flag early on-chain patterns from launch week. There’s a checklist for safe deployment and a few traps to avoid if you’re buying into new B20 tickers.

Editor's note: I watched Base’s B20 go live in early July and the first hours were exactly what you’d expect: a torrent of meme mints, identical supplies, and thin pools that moved on whispers. Our desk tested provenance checks against the 0xB20f factory and the 0xB200 token prefix, which saved time we usually waste on contract spelunking. Conversations with infra teams in July pointed to quick wallet parity but slower explorer upgrades for showing policy states. I’m keeping an eye on the fee-in-B20 plan from Base’s Cobalt notes; if that ships, user onboarding for new tokens could get a lot smoother. — Elliot Veynor

B20 is Base’s native token standard that runs as a precompile inside the node, not as a user-deployed Solidity contract. It mirrors ERC-20 function selectors so wallets and indexers treat B20 like a normal fungible token, but it adds issuer-level controls like transfer policies, role-based permissions, supply caps, freeze-and-seize, memos, and built-in permit. Base activated B20 on July 8, 2026, and has more features queued on the roadmap.

  • Native precompile with ERC-20 parity for UX compatibility
  • Issuer Toolkit: allowlists/blocklists, roles, caps, freeze-and-seize, memos, ERC-2612 permit
  • Deterministic addresses via a factory at 0xB20f…; B20 tokens start 0xB200…
  • Early activity skewed to memecoins; no real RWAs or stablecoins in first sample
  • Planned ability to pay fees in B20 tokens is on Base’s roadmap

How does B20 actually work under the hood?

B20 lives inside Base’s node as a native precompile. Instead of deploying a Solidity ERC-20 contract, issuers call the B20 factory, which mints a token implementation backed by the node’s Rust code. Because the interface mirrors standard ERC-20 selectors, most wallets, indexers, and tools see a B20 token and interact with it like any fungible asset.

The factory sits at a fixed address — 0xB20f000000000000000000000000000000000000 — and tokens created by it have deterministic addresses with a distinctive 0xB200… prefix. That makes basic provenance checks faster and reduces the chance of collisions or weird proxy patterns you sometimes see with contract-based mints. These deployment details, including the selector parity and Issuer Toolkit, are documented in developer explainers and Base references (Chainstack).

Base officially activated B20 on July 8, 2026 as part of its Beryl upgrade cycle, and the upgrade changelog flags it as live on mainnet (Base — Upgrades changelog). The same roadmap notes future improvements tied to Cobalt planning entries, including a path to pay fees in B20 (more on that later).

What separates B20 from ERC-20 in practice?

Function names look the same. Everything else — the execution model, deployment flow, and built-in controls — is different. Think of ERC-20 as “you ship a contract with whatever features you add,” while B20 is “the chain ships the core logic and you flip switches from an issuer console.”

The biggest upgrade is the Issuer Toolkit. Out of the box, B20 supports role-based access, transfer policy rules (allowlists or blocklists), supply caps, freeze-and-seize via burnBlocked, optional on-chain memos, and ERC‑2612 permit for gasless approvals (Chainstack). All of that is native, so issuers don’t need to stitch together third-party libraries and hope audits catch edge cases.

Aspect B20 (Base) ERC-20 (typical) Implementation Native precompile in node (Rust) Solidity/Vyper smart contract deployed by user Selector compatibility Matches ERC-20 function selectors Standard ERC-20 Issuer controls Built-in roles, policies, caps, freeze-and-seize, memos, permit Only if coded in; varies across tokens Addressing Factory: 0xB20f…; tokens deterministic, start 0xB200… Arbitrary contract addresses per deployer Audit surface Shared native logic maintained by the chain Each contract is custom and needs its own audit Gas/efficiency Potentially leaner execution via precompile Depends on contract code; often heavier Fees in token Planned on Base roadmap (EIP‑8130 path) Chain-dependent; not standard

For end users, near-term UX should feel familiar: balances, transfers, approvals, spending via permit. The difference is what issuers can do behind the scenes — from predefining allowed counterparties to freezing assets in compliance events. Whether that’s a feature or a red flag depends on your use case.

What did launch week show on-chain?

On day one, B20 mostly turned into a mint cannon for memecoins. DEXTools pulled registry logs from the first ~7 hours after activation and counted roughly 2,000 B20 tokens created. In a 250-token sample, 98.4% used 18 decimals, 64% set total supply to exactly 1,000,000,000, and there were zero genuine stablecoins or RWAs in the set (DEXTools News).

None of that means B20 can’t host serious assets. It just shows what happens when you lower mint friction on a chain that already loves retail flow. Expect noise before signal. Standards tend to get stress-tested by meme traders first, then picked up by more structured projects once the edges are known.

For now, assume most fresh B20 tickers are experiments or outright punts. If you’re allocating, use small sizes, confirm transfer policies aren’t trapping you, and check who holds the issuer roles before you touch a pool.

How should issuers use the B20 toolkit without painting themselves into a corner?

Issuer power cuts both ways. B20 makes it easy to ship guardrails, but misconfigured policies can wreck UX or liquidity. Start with the minimum viable controls and ramp up only when there’s a clear requirement.

  • Decide roles early. Map who can mint, pause, set policies, and rotate keys. Document recovery paths.
  • Prefer allowlists for pilots, then loosen to blocklists once you’re comfortable with circulation risks.
  • Set a supply cap and stick to it. If you’ll raise it later, pre-announce conditions and timelines.
  • Use memos sparingly. They’re useful for provenance, but keep private data off-chain.
  • Enable permit (ERC‑2612) for smoother DEX flows and fewer failed approvals.

Pro tip: Verify provenance before integration. True B20s minted through the factory come from 0xB20f… and the token address will start 0xB200…. If those two checks fail, treat it as a regular contract token and proceed carefully (Chainstack).

If you’re aiming at regulated use cases, don’t rely on “freeze-and-seize exists” as your whole compliance story. You’ll still need documented procedures, event logs, and disclosures so users understand the circumstances under which you’ll exercise those controls.

What are the risks and trade-offs for holders and developers?

Centralized levers. Freeze-and-seize, blocklists, and role hierarchies can be useful, but they introduce issuer discretion. That’s a problem for censorship-resistance purists and a feature for compliance-minded teams. Either way, investors deserve clear disclosure.

Migration friction. If you’re porting an ERC-20 to B20, there’s no magic “convert” switch. You’ll likely mint a B20 version, set up migration or swap flows, and communicate carefully. Expect double-ticker confusion unless you make the path obvious.

Tooling lag. Selector parity means wallets and indexers should basically work. But specialized features — like reading policy states or listing issuer roles — may need explorer updates. Some analytics and bridges could take a beat to support the B20 factory metadata.

Execution assumptions. Precompiles can reduce custom contract risk and, in some cases, improve efficiency. Still, you’re trusting the chain’s implementation and upgrade process. Read the Base changelog and follow upgrade notes so you’re not surprised by behavioral tweaks (Base — Upgrades changelog).

Infographic of DEXTools’ July 9, 2026 first‑day B20 census — shows ~2,000 tokens created in a ~7‑hour window, 98.4% asset (18‑decimal) variant and 64% with a 1,000,000,000 supply, illustrating the day‑one memecoin surge. — Source: DEXTools News

Will fees in B20 tokens actually arrive, and what would that change?

Base’s roadmap calls out planned B20 enhancements tied to the Cobalt phase, including the ability to pay transaction fees in B20 assets as part of an EIP‑8130 rollout path. It’s listed as a planning entry, not a live feature, but it’s on the official board (Base — Upgrades changelog).

If enabled, fee payment in B20 could soften the classic cold-start problem for new tokens. New users wouldn’t need ETH for gas to move or stake a token; they could pay in the asset itself. That’s great for UX and community growth, but it adds economic design questions around gas pricing, slippage on fee conversions, and abuse vectors. Treat it as a meaningful “watch this space,” not a done deal.

Common Mistakes

  1. Not verifying the factory path. If a token doesn’t originate from 0xB20f… and the address doesn’t start 0xB200…, you might be looking at a contract clone. Check event logs and the factory registry before integrating.
  2. Assuming immutability. B20’s roles and policies mean controls exist by design. If you require permissionless behavior, read the policy state before buying or providing liquidity.
  3. Over-tight transfer rules. Aggressive blocklists or narrow allowlists can trap user funds or kill pool depth. Pilot with small cohorts and monitor revert reasons on transfers.
  4. Ignoring permit. Skipping ERC‑2612 means more failed approvals and higher friction. Enable it and make sure your frontends request signatures correctly.
  5. Supply optics games. Launching with 1,000,000,000 supply because “that’s what memes do” tells on you. Pick decimals and supply that fit your economics, not a template.
  6. Assuming bridges support B20 on day one. Many bridges prioritize standard ERC-20s. Confirm B20 integration before trying to move assets cross-chain.

If you want ongoing coverage of Base upgrades, token standards, and the knocks they take in the wild, we track it closely at Crypto Daily.

Frequently Asked Questions

Can I convert an existing ERC-20 into a B20 without breaking markets?

There’s no in-place conversion. The usual path is to mint a B20 version, set up a swap or migration contract, and communicate a clear cutoff plan. Some teams dual-list during a transition window, but that adds confusion, so keep the overlap short and explicit.

Do B20 tokens work everywhere ERC-20s do?

For basic transfers and approvals, yes — B20 mirrors ERC-20 selectors, so wallets and most dApps treat them as fungible tokens. The issuer-only features are new, so explorers and analytics may need updates to surface policy state or role assignments. Expect that to improve over time.

How do I verify a token is a real B20 and not a lookalike?

Check the provenance. Confirm the mint came from the factory at 0xB20f000000000000000000000000000000000000 and that the token address begins with 0xB200…. Cross-check registry events and avoid tokens that can’t prove a factory origin (Chainstack).

Are transfer memos public, and should I worry about privacy?

Memos are optional metadata. If an issuer enables them, they become part of the token’s on-chain data surface, which is public by default. Don’t include sensitive information; use them for operational breadcrumbs like issuance notes or compliance references.

What happens if an issuer’s admin keys are compromised?

Role-based controls cut both ways. Good setups separate duties and include emergency procedures: freeze suspicious flows, rotate keys, and publish an incident notice. If you hold a token, check whether the issuer has documented recovery steps before you size up exposure.

Can B20 exist outside Base?

B20 is native to Base as a precompile. Other chains would need to implement their own equivalent. You can bridge value or wrap representations to other networks, but those wrappers won’t have Base’s native issuer controls unless the destination chain supports them.

Did launch data imply B20 is only for memes?

No — it implied that mint friction invites experimentation. Early logs showed thousands of quick mints with meme-style parameters and no serious RWAs or stablecoins in a small sample (DEXTools News). Expect more sober use cases as tooling and policy patterns settle.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.



* This article was originally published here

Sunday, August 16, 2026

Licensed Web3 Sportsbooks for Football, NHL and MLB

Licensed Web3 Sportsbooks for Football, NHL and MLB

Crypto betting has moved well beyond niche Bitcoin casinos. Today's Web3 sportsbooks combine licensed gambling operations with blockchain payments, wallet connectivity, and faster settlements. Many also support dozens of cryptocurrencies, allowing bettors to move between Bitcoin, Ethereum, USDT, Solana, TRON, and other assets without relying on traditional banking.

The challenge is that not every crypto sportsbook delivers the same experience. Some focus primarily on casino games and treat sports as a secondary product. Others offer excellent football coverage but only basic markets for North American leagues. Licensing is another important distinction. A licensed operator must comply with regulatory standards, while blockchain features add transparency and payment flexibility.

This review looks at five licensed Web3 sportsbooks that perform particularly well for three of the world's most popular betting markets:

  • Football (soccer)

  • NHL

  • MLB

What Makes a Good Web3 Sportsbook?

A modern crypto sportsbook should provide more than cryptocurrency deposits. The strongest platforms combine several features.

  • A recognized gambling license

  • Multi-chain crypto support

  • Competitive odds

  • Extensive live betting

  • Fast crypto withdrawals

  • Wallet connectivity

  • Transparent settlement procedures

  • Responsive mobile experience

Football bettors usually look for broad league coverage and live markets. NHL bettors benefit from sportsbooks with frequent odds updates during games, while MLB bettors need reliable live betting throughout every inning.

Licensed Web3 Sportsbooks

Sportsbook

License

Crypto Support

Best For

Dexsport

Anjouan

40+ cryptocurrencies

Overall Web3 experience

Cloudbet

Offshore licensed

30+ cryptocurrencies

High-volume sports betting

Stake

Offshore licensed

17+ cryptocurrencies

Large crypto ecosystem

Vave

Curaçao

Multiple cryptocurrencies

Football markets

Thunderpick

Offshore licensed

Crypto only

Esports and traditional sports

1. Dexsport

Dexsport is one of the few sportsbooks built around blockchain rather than simply accepting cryptocurrency payments. Players can connect MetaMask, Trust Wallet, or register with email or Telegram, while keeping control over how they fund their accounts.

The platform supports more than 40 cryptocurrencies across 20 blockchain networks, making it one of the broadest selections among licensed sportsbooks. Football receives particularly strong coverage, ranging from domestic leagues to Champions League and international tournaments. NHL and MLB are equally well represented with pre-match and live betting.

One feature that separates Dexsport from many competitors is its public betting desk. Bets and settlements can be viewed transparently, giving players additional confidence in how wagers are handled. The platform has also undergone audits by CertiK and Pessimistic and operates under an Anjouan gaming license.

Highlights

  • 40+ cryptocurrencies across 20 networks

  • MetaMask and Trust Wallet support

  • No mandatory KYC for standard play

  • Cash Out on live bets

  • Transparent on-chain betting records

  • Strong football, NHL, and MLB coverage

2. Cloudbet

Cloudbet has been serving crypto bettors since 2013, making it one of the longest-running sportsbooks in the industry. Rather than chasing casino promotions, it has focused on building a sportsbook with deep markets and high betting limits.

Football coverage extends across Europe's top leagues, international competitions, and lower divisions. NHL and MLB are equally comprehensive, making Cloudbet particularly attractive for North American sports fans.

The sportsbook supports more than 30 cryptocurrencies and generally processes withdrawals automatically within minutes or hours, depending on network congestion.

Highlights

  • Excellent football, NHL, and MLB coverage

  • High betting limits

  • 30+ cryptocurrencies

  • Competitive odds

  • Fast automated withdrawals

3. Stake

Stake has become one of the largest names in crypto gambling, combining sportsbook and casino products under a single account.

The sportsbook covers more than 30 sports with extensive live betting, streaming, and Cash Out functionality. Football receives the deepest coverage, while NHL and MLB offer competitive odds and numerous betting options throughout the season.

Stake accepts more than 17 cryptocurrencies and provides one of the strongest live betting interfaces currently available. Players should note that identity verification is required before withdrawals.

Highlights

  • Excellent football markets

  • Live streaming

  • Cash Out

  • Competitive sportsbook margins

  • Large cryptocurrency selection

4. Vave

Vave combines sportsbook and casino gaming within a modern interface that performs particularly well on mobile devices.

Football is clearly the platform's strongest category. Major European matches often include hundreds of available betting markets, while NHL and MLB coverage remains solid throughout the season.

The sportsbook supports numerous cryptocurrencies and provides live betting, streaming, and player proposition markets. Identity verification generally takes place during larger withdrawals rather than registration.

Highlights

  • Deep football markets

  • Live betting

  • Cash Out

  • Mobile-friendly interface

  • Good cryptocurrency support

5. Thunderpick

Thunderpick originally built its reputation through esports, but its traditional sportsbook has expanded considerably over the past few years.

Football remains the strongest conventional sport, while NHL and MLB coverage continues to improve. Bettors interested in combining traditional sports with CS2, Dota 2, Valorant, or League of Legends will appreciate having everything available under one account.

The sportsbook is entirely crypto-based and supports several major digital assets for deposits and withdrawals.

Highlights

  • Strong esports offering

  • Football, NHL, and MLB coverage

  • Crypto-only platform

  • Regular sportsbook promotions

Which Sportsbook Performs Best by Sport?

Football

Football demands broad league coverage, fast live odds, and numerous betting markets.

Top choices

  1. Dexsport

  2. Cloudbet

  3. Stake

  4. Vave

  5. Thunderpick

NHL

Hockey bettors benefit from sportsbooks that update live odds quickly and offer a wide range of player and game markets.

Top choices

  1. Cloudbet

  2. Dexsport

  3. Stake

  4. Vave

  5. Thunderpick

MLB

Baseball rewards sportsbooks that provide stable live betting throughout every inning and support advanced betting markets.

Top choices

  1. Cloudbet

  2. Dexsport

  3. Stake

  4. Vave

  5. Thunderpick

Choosing the Right Platform

The best sportsbook depends on what matters most.

Cloudbet remains one of the strongest choices for experienced sports bettors who prioritize market depth and high betting limits. Stake delivers one of the largest crypto gambling ecosystems with an excellent live betting interface. Thunderpick is particularly attractive for players who divide their time between esports and traditional sports.

Dexsport offers the most complete Web3 experience. It combines a gambling license, extensive multi-chain support, wallet connectivity, blockchain transparency, and comprehensive coverage of football, NHL, and MLB. For bettors looking for a sportsbook built around cryptocurrency rather than simply accepting it as a payment method, it stands out as one of the strongest options available today.

 

 

 

Disclaimer: The information here is provided for general purposes only and is not legal, tax, investment, or financial advice, and nothing here is a betting tip or prediction. Market availability and platform features change over time, so confirm current details before betting. Betting carries risk, and rules vary by country, so check the law where you live. Please gamble responsibly, within your means, and only if you are of legal age.



* This article was originally published here

Saturday, August 15, 2026

AbbVie Earnings: Can Skyrizi and Rinvoq Replace Humira?

AbbVie Earnings: Can Skyrizi and Rinvoq Replace Humira?

Picture an earnings call where one question keeps looping: can two fast-growing immunology drugs really replace a mega-blockbuster that defined a decade of pharma profits? That’s the AbbVie story in a sentence.

Portfolio managers now model every quarter around the same pivot: Humira is sliding post-biosimilars; Skyrizi and Rinvoq are sprinting. The gap is the whole ballgame.

If you care about cash flow durability, margins, and what happens when a moat meets generics, this is the stack to watch.

Humira’s patent exclusivity broke in Europe years ago and in the U.S. in 2023, opening the door to a swarm of adalimumab biosimilars. That forced AbbVie to do what every big pharma hopes it never has to do: rebuild the core from inside. The plan is clear enough. Let Humira decline at a managed pace while Skyrizi (risankizumab, an IL‑23 inhibitor) and Rinvoq (upadacitinib, a selective JAK inhibitor) scale across dermatology, rheumatology, and gastroenterology.

AbbVie’s earnings hinge on a handoff: defend Humira’s base just long enough for Skyrizi and Rinvoq to reach escape velocity across multiple indications and geographies.

Why now? Because post‑loss‑of‑exclusivity curves don’t wait. Payers re-tier. Net prices reset. Prescribers experiment. Patients ask about cheaper options. The company either backfills revenue fast or the P&L re-rates.

Humira’s Peak, Then the Patent Cliff

Humira was the archetypal mega‑blockbuster: multiple autoimmune indications, years of IP layers, and a massive commercial engine. But time always wins. Europe saw biosimilars earlier, and the U.S. followed in 2023 as a pack of adalimumab copies arrived, including interchangeable versions like Cyltezo, validated at the agency level by the FDA years prior (FDA).

The erosion mechanics are familiar. You get a stair‑step decline as contracts renew, formularies shift, and net price blends compress. The question for investors isn’t whether Humira declines. It’s the slope of the line and whether new revenue can outrun it.

How Skyrizi and Rinvoq Are Built to Take Share

Skyrizi and Rinvoq weren’t accidents. AbbVie designed them to cover broad autoimmune ground, with mechanisms that fit the current standard of care debates: targeted cytokine inhibition for Skyrizi; a potent but selective JAK for Rinvoq. Each one has stacked indications over time as data matured and regulators weighed in.

Indications and label expansion

Skyrizi first broke through in moderate to severe plaque psoriasis, then gathered momentum in psoriatic arthritis and inflammatory bowel disease as data landed. U.S. labels reflect that breadth today, spanning psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (AbbVie Prescribing Information).

Rinvoq started in rheumatoid arthritis and has since expanded into atopic dermatitis, psoriatic arthritis, ankylosing spondylitis/axial spondyloarthritis, ulcerative colitis, and Crohn’s disease, among others, following rigorous clinical programs and risk‑benefit reviews (AbbVie Prescribing Information).

Those expansions matter. Each new indication extends the total addressable market, allows multi‑specialty detailing, and opens new payer contracts. It’s the difference between a niche therapy and a platform franchise.

Access, payer math, and prescriber habits

Market access is the unglamorous engine here. With Humira facing cheaper biosimilars, payers pressure the class on price. But payers and prescribers also value clinical differentiation: dosing convenience, durable response, and safety profiles adapted to long‑term use. That’s where Skyrizi’s IL‑23 story and Rinvoq’s efficacy in difficult‑to‑treat populations give AbbVie real talking points.

It’s rarely linear, though. Prior authorization, step therapy, and rebates can make uptake lumpy quarter to quarter. And for Rinvoq, JAK class scrutiny means more paperwork and careful patient selection, even with selective targeting and extensive safety data baked into labels and REMS where relevant.

  1. Humira biosimilars launch, payers re-tier formularies and renegotiate.
  2. Net prices for adalimumab class compress; prescribers test biosimilars in stable patients.
  3. New starts and switchers seek best efficacy/convenience; Skyrizi and Rinvoq compete on data and dosing.
  4. Payer contracts evolve with indication breadth; access improves as outcomes evidence accrues.
  5. Franchise scale lowers unit costs; commercial reach compounds across specialties.

What Recent Earnings Have Actually Shown

Across recent quarters, the pattern has been pretty consistent: Humira down as expected post‑U.S. biosimilars, while Skyrizi and Rinvoq post strong year‑over‑year growth and sequential gains. Management has repeatedly framed the pair as the company’s primary growth engine and has suggested, in public remarks and investor materials, that they’re positioned to ultimately surpass Humira’s contribution over time, assuming continued execution and label breadth (AbbVie IR).

It’s worth remembering this isn’t just a sales contest. Skyrizi and Rinvoq sell into categories where outcome measures are getting sharper. Dermatology values clear skin rates and durability. GI cares about histologic remission and steroid‑free maintenance. Rheumatology tracks function and flares. AbbVie’s trials have been built around those endpoints, which is central to prescribing behavior and payer decisions.

Franchise Mechanism Key Indications (US) Administration Competitive Set Commercial Notes Humira (adalimumab) TNF inhibitor Multiple autoimmune (legacy) Subcutaneous TNF class + many biosimilars Net price compression after 2023 U.S. biosimilar entry; high brand recognition Skyrizi (risankizumab) IL‑23 inhibitor Psoriasis, PsA, Crohn’s, UC Subcutaneous; IV induction in GI IL‑23/IL‑17/IL‑12/23 rivals Strong skin clearance profile; convenient maintenance dosing; expanding GI footprint Rinvoq (upadacitinib) Selective JAK RA, AD, PsA, AS/axSpA, UC, Crohn’s Oral, once daily JAKs and targeted biologics High efficacy in difficult disease; class safety monitoring and labeling influence access

Regulatory context supports the breadth. U.S. approvals for Skyrizi in psoriasis came first, then psoriatic arthritis and GI indications as data matured; Rinvoq’s initial RA approval extended into dermatology and IBD following robust phase 3 programs and further safety label updates along the way (FDA Approvals Database).

Pricing, Competition, and the Margin Story

Let’s talk math. Humira’s contribution was never just volume. It was margin heft from a mature brand with optimized manufacturing and a long tail of loyal prescribers. Replacing that is about volume and mix. Net prices in immunology are pressured by biosimilars on one side and rival brands on the other. AbbVie can’t ignore either.

Class competition is real

Skyrizi competes in a crowded biologics space where IL‑23s and IL‑17s have real followings. The pitch is efficacy, dosing convenience, and durability. In GI, it also faces anti‑integrins and other targeted mechanisms. That’s healthy competition, but it means share gains are earned, not gifted.

Rinvoq competes against other JAKs and against biologics favored by certain payers for safety familiarity. The JAK class has had higher regulatory scrutiny, including boxed warnings and post‑marketing requirements, which shape prescriber comfort and payer criteria. That doesn’t preclude growth; it just requires relentless data generation and precise positioning.

Net pricing and access pressure

Biosimilars pull reference pricing down across categories, even if not directly substitutable. Expect continuing negotiation cycles as large PBMs and plans attempt to capture savings. For AbbVie, the lever is differentiation proven in head‑to‑head or meaningful indirect comps, plus label expansions that unlock broader contracts.

Manufacturing and patient experience

Friction matters. Skyrizi’s maintenance schedule is a selling point for adherence. Rinvoq’s oral dosing is patient‑friendly. But reliability, supply continuity, and support programs can be tie‑breakers. AbbVie has scale, which helps. It still needs to keep fulfillment boringly predictable.

What To Watch Over the Next Few Earnings Cycles

If you want to know whether Skyrizi and Rinvoq can fully replace Humira, track a handful of concrete milestones and signals.

  1. U.S. and ex‑U.S. indication breadth: Any new approvals or earlier‑line placements for either drug can expand eligible populations. Keep an eye on label updates posted through official channels like the FDA and AbbVie’s own disclosures (AbbVie IR).
  2. Access wins: Watch remarks on formulary positioning, step‑edits removed, and time‑to‑treatment metrics. These often show up in Q&A on earnings calls or slide decks.
  3. Real‑world outcomes: New data on durability, steroid‑free remission, or skin clearance at high thresholds (like PASI 90/100) can reinforce differentiation and support earlier use.
  4. International mix: As Europe and other markets normalize post‑LOE dynamics in their own ways, ex‑U.S. growth for Skyrizi/Rinvoq becomes more important to fill the global hole.
  5. Manufacturing and supply: Any scale‑up milestones or site validations that de‑risk supply constraints for subcutaneous and oral inventories will matter to sustained growth.
  6. Safety communications: Updated class guidance for JAKs or new long‑term safety readouts can influence prescriber comfort and payer criteria for Rinvoq in particular.

Risks & What Could Go Wrong

  • Uptake lags: If payer hurdles or prescriber caution slow new starts, growth could underwhelm while Humira erosion continues.
  • Pricing compression: Competitive rebating or biosimilar adjacency could squeeze net prices faster than volume ramps.
  • Safety headlines: Class‑wide JAK concerns or unexpected safety signals could lead to label changes or tighter access for Rinvoq.
  • Clinical misses: Any negative late‑stage readout or a competitor’s superior data in a core indication could dent share curves.
  • Supply chain hiccups: Capacity constraints or quality holds would quickly show up as missed demand in high‑growth markets.
  • Macroeconomic pressure: Higher patient cost‑sharing or plan design changes could delay starts or increase discontinuations.

Replacement isn’t a single quarter event; it’s a sequence of flawless quarters. A wobble in access, safety, or pricing can push the crossover further out.

Where I’m Tracking This Story

If you want a steady drumbeat on how immunology franchises are trending around earnings season, I keep an eye on company filings and primary sources. For broader market color and how biotech intersects with risk appetite across assets, I also read outlets like Crypto Daily to see how flows and sentiment are shifting at the macro level. Different market, same discipline: watch the data, ignore the noise.

Frequently Asked Questions

What exactly are Skyrizi and Rinvoq replacing?

They’re positioned to backfill revenue and profit that AbbVie historically drew from Humira, a top‑selling anti‑TNF biologic that’s now under intense biosimilar pressure in the U.S. and already faced it in Europe. The replacement goal is financial, not therapeutic one‑for‑one.

How do Skyrizi and Rinvoq work differently from Humira?

Humira targets TNF, a broad inflammatory cytokine. Skyrizi selectively inhibits IL‑23, which has shown strong skin and GI outcomes. Rinvoq is a selective JAK inhibitor, oral and potent, affecting intracellular signaling pathways. Different mechanisms, overlapping disease areas.

Is there a clear timeline for when the pair might surpass Humira?

Management has suggested the combination is positioned to overtake Humira’s contribution over time as labels expand and access improves, but exact timing depends on uptake, pricing, and competition. Watch consecutive quarters of double‑digit growth and commentary from AbbVie IR for clues.

What are the biggest bottlenecks to faster adoption?

Payer controls like step therapy and prior authorization, prescriber caution around JAK class safety for Rinvoq, and competition from other biologics in dermatology, rheumatology, and GI. Supply reliability and patient support programs also influence real‑world uptake.

Do biosimilars to Humira directly hurt Skyrizi and Rinvoq?

Indirectly. Cheaper adalimumab options push down immunology net price expectations. That can make payers tougher negotiators across the board. Still, if clinical differentiation is clear, premium brands can keep favorable access and share.

Which datapoints should investors watch each quarter?

Year‑over‑year and sequential sales growth for Skyrizi and Rinvoq, Humira decline slope, commentary on formulary wins, any label updates, and margin trends. Also note any safety communications or manufacturing updates in press releases or filings.

Where can I verify approvals and labels?

Check the FDA’s approvals and labeling database for official updates (FDA) and the current U.S. Prescribing Information for Skyrizi and Rinvoq provided by AbbVie (Skyrizi PI; Rinvoq PI).

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.



* This article was originally published here

Friday, August 14, 2026

How Crypto Casino Licensing Differs Across Europe

How Crypto Casino Licensing Differs Across Europe

"Licensed in Europe" sounds like a single standard, and it is not. Europe contains some of the strictest gambling regulators in the world and some of the lightest, and the distance between them decides how much protection a player actually has.

A licence from one European jurisdiction can mean segregated funds and a binding disputes body; from another, far less.

This walks through the main European licensing regimes a crypto casino might hold, what each brings a player, and why most crypto-first casinos sit outside the strictest of them. The continent is not one market but many, and the licence tells you which one you are in.

Europe Is Not a Single Regulator

The first thing to unlearn is that a European licence is a uniform guarantee. Gambling regulation in Europe is national, not continental, so each country sets its own regime, and they vary enormously.

Shared standards come through the European Union's anti-money-laundering directives, but licensing itself stays with member states and a few well-known non-EU jurisdictions.

So a casino "licensed in Europe" could be under a rigorous EU regulator or a lighter one, and the country named is what matters, not the continent.

Malta: The EU Tier-1 Standard

The Malta Gaming Authority is the reference point for serious online gambling regulation in the EU, and the strictest a crypto casino commonly holds.

An MGA licence brings segregated player funds held separately from operating capital, a binding player-protection disputes process, and access to the EU market under a recognised regulator.

It is demanding and expensive to obtain, which is precisely why relatively few crypto-first casinos carry it, and why the ones that do can point to it as a genuine mark of standing. For a player, a Malta licence is the strongest routine assurance available in Europe.

Estonia, Isle of Man and Gibraltar: Established Regimes

Below Malta sit several well-regarded European regimes, each with its own character.

Estonia licenses online gambling under an EU framework, with a modern regulator that has become a credible base for operators wanting EU standing without Malta's scale. The Isle of Man and Gibraltar, both outside the EU but long-established in gambling, run respected regimes with strong reputations, particularly among larger operators. Each brings meaningful oversight and player protection, and while their specifics differ, all three sit well above the lightest offshore options, and what a given regime actually covers is worth checking against the country named.

Curacao: European-Facing but Not European

Curacao deserves a place here because it licenses so many crypto casinos serving European players, even though it is not a European regulator.

In recent years Curacao overhauled its framework, moving to direct licensing by its Gaming Authority with a public register and stronger oversight than its old sublicence system offered.

It is more credible than it was, but it remains a Caribbean jurisdiction, not an EU one, so a Curacao-licensed casino serving European players does not carry EU-level protections like segregated funds or a binding EU disputes body.

Dexsport's Licensing and European Players

Dexsport holds an Anjouan licence, which is an offshore regime outside Europe entirely, and lighter than Malta, Estonia or the Isle of Man. Stating that plainly is the honest starting point for any European player weighing the platform.

What that means in practice is thinner formal recourse than an EU licence provides: there is no EU segregated-funds requirement or binding European disputes body behind an Anjouan licence.

Where Dexsport answers part of that structurally is its non-custodial model, which keeps a settled balance in a wallet the player holds instead of an operator account, and its public on-chain desk, which records settlement independently.

Those are real features, and they are a different kind of assurance from an EU licence, not a substitute for one. A European player should weigh the lighter licence against the self-custody model directly. Anjouan also excludes several territories, so players should confirm their own jurisdiction is served.

Reading a European Licence for What It Is

The practical takeaway is to read the specific jurisdiction, never the word "Europe." A Malta or Estonia licence carries EU-level protections; an Isle of Man or Gibraltar licence carries a strong established regime; a Curacao or Anjouan licence is offshore, lighter, and outside EU protections however it is marketed.

Verifying the licence on the regulator's own register is the step that confirms which of these you are actually dealing with.

Confirm what is legal where you live, keep stakes within a set budget, and play only if you are of legal age, since KYC or AML checks may apply. Responsible gambling matters under every regime, because the strongest European licence does not change the house edge on a single game.

 

 

 

Disclaimer: The information here is provided for general purposes only and is not legal, tax, investment, or financial advice. Licensing regimes and their requirements vary by jurisdiction and change over time, so confirm current details with the relevant authority. Betting carries risk, and rules vary by country, so check the law where you live. Please gamble responsibly, within your means, and only if you are of legal age.



* This article was originally published here

Wednesday, August 12, 2026

AI Stock Selloff: What It Means for the S&P 500

AI Stock Selloff: What It Means for the S&P 500

AI stocks finally hit turbulence. The kind that makes you grip the armrest and wonder if the pilot just banked too hard. The move didn’t stay in one corner of the market either. It spilled straight into the S&P 500, which had leaned heavily on AI all year for momentum.

So let’s cut through the noise. What actually cracked, what didn’t, and what it could mean for the next few months if you’re tracking the index or running money against it.

I’ll keep it plain: leadership concentrated in a handful of AI and chip names is great when they run. It’s a shock absorber in reverse when they all slip at once.

Point Details Index wobble on AI weakness The S&P 500 fell 64.87 points (‑0.86%) to 7,468.83 on July 17 as an AI and chip selloff broadened across sectors Reuters (via MarketScreener). Semis show the shock The PHLX Semiconductor Index (SOX) tumbled about 17% in July to that point, though it remained up roughly 63.2% year‑to‑date, underscoring volatile leadership Reuters (via MarketScreener). Volatility didn’t stop mid‑month On July 28, the SOX closed at 11,035.68, down 519.20 points (‑4.49%) on the day, showing continued late‑July pressure Nasdaq. Big Tech also took a hit Every member of the AI‑exposed “Magnificent Seven” slipped on July 17; Meta fell about 2.7% and Alphabet about 3.2% Reuters (via MarketScreener). Earnings support is still there Analysts aggregated by LSEG expected roughly 26% year‑on‑year S&P 500 earnings growth for Q2, a key backdrop to this year’s index strength Reuters (via MarketScreener, citing LSEG).

AI leaders hit: what actually changed

When chips and AI mega caps roll over together, the index loses its engine. On July 17, that’s exactly what happened. The S&P 500 dropped 0.86% as chip weakness spread and the whole AI complex caught a downdraft Reuters. Even the heavyweight platforms weren’t spared. Meta and Alphabet fell materially that day as investors marked down near‑term AI spending optimism and got more demanding about payoff timelines.

Two quick points. First, the leadership was narrow for months, so a synchronized pullback always risked becoming a headline event. Second, this wasn’t just one bad print. The SOX kept flashing stress late in July, including a 4.49% slide on the 28th Nasdaq. That tells you positioning was crowded and sensitive to guidance tweaks, supply updates, and capex chatter.

Pro tip: Watch the second derivative in guidance. If managements say AI spend is still rising but the pace is cooling, the market often hears “margin pressure.”

How concentrated is the S&P 500 right now

You don’t need the exact percentages to feel the concentration. A handful of mega caps have been doing a lot of the heavy lifting for both price and earnings. That concentration works beautifully when revenue beats and AI narratives line up. It also means the index can slip on days when only a few names wobble.

What really matters is breadth. If mid and small caps lag while the top tier takes a breather, the index loses its cushion. If breadth improves while leaders cool, you can dodge deeper downside. So the question isn’t only “are AI names selling off,” but also “is the rest of the market stepping in.”

Keep an eye on advance‑decline lines, equal‑weight S&P performance versus the cap‑weighted index, and sector dispersion. A stabilizing equal‑weight ratio often hints that leadership is rotating instead of fully breaking.

Semiconductor whiplash and the SOX signal

Semis are the tip of the AI spear. Their July move was wild: down roughly 17% partway through July, yet still up about 63% year to date at that point Reuters. That’s concentration and momentum in one snapshot.

Why such whiplash? The AI build‑out is real, but the supply chain is complex. Foundry capacity, advanced packaging, memory pricing, networking gear, power delivery, data center construction, and even grid constraints all matter. A hiccup in any of those can ripple through orders and margins. When estimates get stretched, even a small tweak in lead times or utilization can trigger big price reactions.

One more nuance: the late‑July drop of 4.49% in the SOX on the 28th shows the pullback wasn’t a one‑and‑done event Nasdaq. That suggests investors were recalibrating how fast hyperscaler capex can scale and how much of the profit pool chips will capture versus software and services.

Semis usually sniff out the turn first. Watch their reaction to guidance more than the guidance itself.

Earnings math: why 26% growth matters

The bullish case hasn’t evaporated. As of mid‑July, aggregated LSEG data pointed to around 26% year‑over‑year S&P 500 earnings growth for Q2 Reuters (citing LSEG). That helps explain the resilience. If earnings beats keep coming and forward guidance holds up, the index can absorb pockets of AI volatility.

The bear case is about the mix. If a large slice of that earnings growth rests on AI‑exposed companies, then wobbles in that group carry outsized consequence. It’s not that the rest of the market has no growth. It’s that the multiple and expectations are richest where the narrative is hottest. A little disappointment can move a big market cap base.

Pro tip: Track revisions breadth, not just headline EPS beats. If estimate upgrades narrow to a few AI names while downgrades creep into cyclicals and defensives, the index gets more fragile.

Valuation stress test: what if AI spend slows

Scenario 1: AI spend grows, but slower

Hardware bookings decelerate, unit growth re‑phases, and margins compress a touch. In this case, leaders can still work, but the market often rotates toward more reasonably priced cyclicals or quality cash generators. The S&P 500 might chop sideways while breadth improves.

Scenario 2: Guidance resets lower

Capex plans get pushed out or reprioritized. You can see multiple compression in semis and select hyperscaler suppliers. The index impact depends on whether financials, healthcare, or industrials can offset the drag. Watch for a short, sharp derating that tries to find a new floor.

Scenario 3: Demand surprises on the upside

New use cases or cost paybacks show up faster. That can re‑ignite leadership and pull the index higher again. But it may also bring fresh volatility as supply chains strain to keep up.

Risk check: Across all scenarios, concentration risk doesn’t disappear. Even a healthy AI path can be bumpy for prices when positioning is crowded.

Portfolio implications for S&P 500 trackers

Practical steps for the next 60–90 days

  • Revisit rebalancing cadence. If you typically rebalance quarterly, consider whether more frequent, rules‑based trims on outsized winners make sense within your mandate.
  • Compare cap‑weighted versus equal‑weight exposures. A partial equal‑weight sleeve can smooth concentration shocks without abandoning index beta.
  • Mind your factor mix. Quality balance sheets and free cash flow tend to travel well through guidance resets.
  • Define drawdown rules before earnings waves hit. Pre‑set triggers reduce emotional decisions if more AI guidance haircuts show up.

Hedging menu, in plain English

Tool What it helps with Watchouts Index puts or put spreads Direct S&P 500 drawdown protection Premium decay if the selloff fades; sizing matters Covered calls on AI leaders Income against elevated implied volatility Upside is capped if the rebound is sharp Sector rotation Reduce reliance on one theme Timing risk if leadership resumes quickly Equal‑weight overlays Dampen single‑name shock May lag in strong mega cap rallies

Pro tip: If you hedge with options, stage entries around catalysts. Pricing often spikes into earnings and cools a few sessions after.

Signals to watch through earnings season

  • Hyperscaler capex language. Are budgets shifting from GPUs to networking, memory, or software? Subtle mix changes can move supplier margins.
  • Foundry and packaging lead times. Easing bottlenecks can temper price power, while new constraints can reheat supply concerns.
  • Memory pricing and inventory. DRAM and HBM dynamics feed directly into AI server cost curves.
  • Order visibility. Are backlog comments getting shorter or more cautious?
  • Earnings revisions breadth. Do upgrades stay concentrated in the same ten names, or broaden across sectors?
  • Market breadth measures. Equal‑weight S&P, advance‑decline lines, and new highs vs new lows will tell you if rotation is constructive.
  • Volatility term structure. A steep front end often flags near‑term event risk; a calm curve can hide tail risk if positioning is one way.

Common pitfalls when AI leaders wobble

  • Chasing every dip as if it’s 2023. Regimes change. Treat each bounce on its own merits and guidance tone.
  • Ignoring the rest of the index. If defensives or industrials quietly improve, that matters for the S&P 500 even if AI cools.
  • Confusing narrative with numbers. Strong stories can mask thinning margins or slower deal cycles.
  • Over‑hedging into the hole. Protection is useful, but crowding into puts after a big slide can be expensive.
  • Anchoring to peak multiples. If the cost of capital is firm and growth moderates, multiples can compress without a recession.

Cross‑asset angle: will crypto feel this

Different market, same risk appetite. When the biggest U.S. stocks have a wobble, it can bleed into broader risk sentiment. Crypto isn’t mechanically tied to semis, but liquidity conditions, dollar moves, and volatility regimes often rhyme. If AI leaders keep chopping, expect more two‑way price action in other risk assets too.

One thing to watch is whether equity volatility lifts while rates stay range‑bound. That mix can push cross‑asset funds to trim exposure in clusters, sometimes hitting unrelated assets for short spurts. It’s less about fundamentals and more about balance sheets and VaR models doing their thing.

What the recent data says about next steps

Three reads from July stand out. First, the S&P 500’s 0.86% drop on July 17 came with broad participation on the downside, not just one or two culprits Reuters. Second, the SOX’s earlier 17% month‑to‑date slide showed how fast leadership can give back gains even inside a strong year to date Reuters. Third, the late‑month 4.49% fall underscored that volatility persisted into the earnings heartland, not just around one headline day Nasdaq.

Layer those on top of roughly 26% expected Q2 earnings growth for the index from LSEG aggregates, and you get a market trying to balance strong fundamentals with stretched positioning Reuters (citing LSEG). That’s not a contradiction. It’s two truths at once. Growth can be real and still too richly valued at the margin for a week or a month at a time.

Crypto Daily covers this cross‑current daily, from earnings to on‑chain data, because the same risk levers move both worlds. If you want a single feed that treats equities and digital assets as one macro puzzle, you know where to find us at Crypto Daily.

Frequently Asked Questions

Did the AI selloff cause the S&P 500 drop on July 17?

It was a major driver. Chip weakness spread into big AI‑exposed tech names and pulled the index lower by 0.86% that day, per reporting at the time.

Are semiconductors still leading the market after the July pullback?

They remain central to the AI story, but July showed leadership can swing fast. The SOX was down about 17% mid‑July and also fell 4.49% on July 28, so volatility is still elevated.

How can the S&P 500 hold up if AI stocks weaken?

Through rotation. If earnings strength broadens to other sectors and equal‑weight measures stabilize, the index can digest AI softness without a deeper drawdown.

What’s the key earnings metric to track now?

Revisions breadth. The LSEG call for roughly 26% Q2 growth is supportive, but where upgrades and downgrades cluster will set the tone for index stability.

Is this a short‑term shakeout or a trend change?

Too early to call. Watch guidance language from AI leaders, hyperscaler capex trajectories, and supply chain signals. If those cool together, the drift can last longer.

Should investors switch from cap‑weight to equal‑weight S&P exposure?

It depends on mandate and risk tolerance. A partial equal‑weight sleeve can reduce concentration risk, but it may lag if mega caps quickly regain leadership.

Does this have implications for crypto markets?

Potentially. When equity volatility jumps and funds de‑risk, some crypto assets can see knock‑on effects as part of broader risk management.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.



* This article was originally published here

Tuesday, August 11, 2026

Slots and Roulette at Crypto Casinos: 5 Platforms Reviewed

Slots and Roulette at Crypto Casinos: 5 Platforms Reviewed

Slots and roulette are the two games that define a casino floor, and on a crypto casino, they come from the same studios that supply everywhere else. The chain a platform runs on does not change who built the game or what its house edge is.

What varies between crypto casinos is the breadth of the library, the studios they carry, and how funding works around the play. This reviews five platforms on those grounds, for players who care about slots and table games specifically.

The Games Are Third-Party, Almost Everywhere

A point worth stating plainly before any review: the slots and roulette tables at nearly every crypto casino are made by outside studios, not the casino itself.

Providers such as Pragmatic Play, Evolution, NetEnt, Hacksaw Gaming and Play'n GO supply the same games across countless platforms. This matters for two reasons.

It means game quality is largely a question of which studios a casino carries, and it means the provably-fair verification some crypto casinos advertise usually covers only their own in-house titles, not these third-party slots and tables.

Five Platforms on Their Casino Libraries

Ordered on the breadth and provenance of their slots and table-game catalogues, which is what a casino-first player is choosing between.

1. Dexsport

Dexsport carries a large third-party library with the studios a slots player looks for, and pairs it with a non-custodial funding model that most casinos do not offer.

  • Slots at the centre: several thousand titles with slots as the largest category, from Pragmatic Play, Evolution, NetEnt, Hacksaw Gaming, Play'n GO and other established studios.

  • Roulette from named live providers: Pragmatic Play and Evolution supply the roulette tables, including live-dealer formats, the same content found at major online casinos.

  • Demo mode before real funds: many games are playable in demo, so the library can be tested without depositing.

  • Non-custodial funding: play is funded from a wallet the player holds across 50-plus coins and 23 networks, and winnings settle back to it.

2. BC.Game

A very large library and a long track record, under a Curacao Gaming Authority licence.

  • Extensive catalogue spanning thousands of zslots and table games.

  • In-house Originals alongside third-party studios, a suite this platform actually maintains.

  • Broad coin support for funding across many assets.

3. Stake

Wide game coverage paired with a heavily marketed live-casino section.

  • Deep slots and table games from the major studios.

  • Branded live tables produced in partnership with providers.

  • Streaming and events built around the casino product.

4. Mega Dice

A Telegram-first casino with a substantial provider lineup.

  • Thousands of games across slots and tables.

  • Around 50 providers supplying the library.

  • Telegram-native access for players who prefer it.

5. BetPanda

A slots-heavy library with a cashback focus.

  • Several thousand slots as the core of the offering.

  • Cashback promotions aimed at regular play.

  • Multi-network funding, though its licensing is not clearly published.

Roulette Is Roulette, Wherever You Play It

One caution specific to table games. The house edge on roulette is fixed by the wheel, not the platform, so a European single-zero wheel carries the same edge on every casino that offers it.

No crypto casino changes that maths, and a platform advertising roulette is offering the same game at the same edge as the next one.

What differs is which variants a casino carries, single-zero versus double-zero, live-dealer versus RNG, and what provably-fair proof does and does not cover on these third-party tables.

What Crypto Adds Around the Games

The games are shared; the funding and record-keeping are where crypto casinos differ from fiat ones and from each other. Non-custodial platforms settle winnings to a wallet the player holds, and hybrid on-chain platforms record settlement publicly.

Neither changes the slot's return-to-player or the roulette wheel's edge, and how an on-chain casino differs from a traditional site sits in the funding and the record, not in the games themselves.

RTP Is the Number Worth Checking

Return-to-player, or RTP, is the long-run percentage a slot pays back, and it is the single most useful number a slots player can check before spinning.

A slot with a 96% RTP returns, over a very long run, 96 of every 100 wagered, with the remaining 4 the house edge. The figure is set by the game's studio, not the casino, so the same slot carries the same RTP across every platform that hosts it.

Some studios ship a game in multiple RTP versions, though, and a casino chooses which to run, so a diligent player checks the RTP shown in the game's own info panel instead of assuming. It does not change that the edge favours the house on every spin; it just tells you by how much.

Choosing on the Library, Not the Chain

For a slots-and-roulette player, the platform choice comes down to which studios a casino carries, whether demo play is available, and how funding works, not to the blockchain underneath. The games are the same third-party titles across the category.

Confirm what is legal where you live, keep stakes within a set budget, and play only if you are of legal age, since KYC or AML checks may apply. Responsible gambling applies to slots and roulette especially, where the house edge is built into every spin and every wheel.

 

 

 

Disclaimer: The information here is provided for general purposes only and is not legal, tax, investment, or financial advice. Game libraries, providers, and platform features change over time, so confirm current details before playing. Betting carries risk, and rules vary by country, so check the law where you live. Please gamble responsibly, within your means, and only if you are of legal age.



* This article was originally published here

Base B20 Token Standard: How Native Tokens Differ From ERC-20

Base just switched on something big for token builders: a native token standard called B20. If you’ve been minting ERC-20s for years, B20 ...